IR

IRIDEX CorpNASDAQ IRIX Stock Report

Last reporting period 30 Mar, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.029

Micro

Exchange

XNAS - Nasdaq

IRIX Stock Analysis

IR

Uncovered

IRIDEX Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-4/100

Low score

Market cap $B

0.029

Dividend yield

Shares outstanding

16.007 B

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 130 full-time employees. The Company’s laser consoles products consist of Glaucoma, which includes Cyclo G6 laser and delivery devices used for the treatment of glaucoma; Medical Retina product, which includes IQ 532 Laser and IQ 577 Laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases, and its PASCAL Synthesis Photocoagulator for the treatment of retinal diseases; Surgical Retina, which includes OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. Its laser probes products consist of Glaucoma, which include MicroPulse P3 Probe, G-Probe and G-Probe Illuminate, and Surgical Retina probes, which include EndoProbe family of products used in vitrectomy procedures.

View Section: Eyestock Rating